TRANSTHERA-B

TransThera Sciences-B opened slightly higher and traded in a narrow range during the morning session, with the latest price at HKD 10.60, up 17.65% from its 52-week low of HKD 9.01 but still 98.44% below the 52-week high of HKD 679.50. The stock remains well below its MA60 (HKD 17.314) and MA20 (HKD 10.528), with a year-to-date decline of 90.64%. Near-term catalysts include the NMPA approval of its proprietary drug 'Yochanra' for bile duct cancer and the completion of the global Phase III trial enrollment, which previously drove a single-day surge of nearly 20%. However, the company continues to report losses, with a Q4 2025 net loss of HKD 96.2 million, up 58.41% YoY, and no operating revenue, while its price-to-book ratio stands at 9.36x, indicating persistent financial strain.

Transthera-B opened higher and rallied in the morning session, closing up 5.07% at HKD 11.18, with an intraday low of HKD 10.59 and high of HKD 11.18, on turnover of 5.9975 million shares and a turnover rate of 1.92%. The rally was driven by China's NMPA approval for its core product Tinengotinib (Yaochangra) for bile duct cancer marketing, boosting the stock at the open. Financially, the company remains unprofitable, with Q4 2025 EPS of -HKD 0.2424 and net loss of -HKD 96.24 million, widening 52.23% YoY, but pipeline progress captured market attention. The stock is 98.35% below its 52-week high of HKD 679.5 and down 90.12% YTD, hovering above the MA20 (HKD 10.58) yet well below the MA60 (HKD 20.10), indicating a deeply depressed price position. However, the company's ongoing share buybacks and equity incentives, along with a prior 40% surge on buyback news, suggest elevated short-term volatility.

Transthera fell sharply today after an initial morning spike, closing at HKD 10.66, down 5.16% from the previous close of HKD 11.24, with an intraday high of HKD 11.67 and low of HKD 10.66. The pullback was primarily driven by profit-taking after the market had already priced in yesterday's NMPA approval for its core drug Tinengotinib in cholangiocarcinoma. The stock had surged over 40% last week on buyback announcements and clinical trial progress, opening about 3% higher today before reversing. Financially, the company remains loss-making, with a net loss of approximately HKD 96.2 million in the latest quarter, widening 58.41% YoY, and EPS of -HKD 0.2424, with zero operating revenue. Price-wise, the stock is 98.43% below its 52-week high of HKD 679.5, but only 18.31% above its 52-week low of HKD 9.01. It trades well below the 60-day MA of HKD 22.005 but above the 20-day MA of HKD 10.537, highlighting recent volatility. However, the long-term commercial value of the new drug approval remains unproven.

Yolanda Biotech (2617.HK) opened at HK$13.250 in the morning session and closed at HK$13.460, surging 16.74% from the previous close of HK$11.530, primarily driven by the company's recent buyback and equity incentive plans, including an announced buyback of up to RMB 100 million, and the completion of global Phase III enrollment for its core product Tinengotinib in advanced cholangiocarcinoma. The current price of HK$13.460 is 98.02% below the 52-week high of HK$679.50 (September 15, 2025), but has rebounded 49.39% from the 52-week low of HK$9.01 (June 24, 2026), and has surpassed the 20-day moving average of HK$10.643, though it remains below the 60-day moving average of HK$22.696, indicating near-term support but long-term weakness. With a P/E of -16.96x, P/B of 12.06x, and market cap of approximately HK$5.56 billion, today's turnover of only HK$18.2 million with a turnover rate of 0.45% suggests the rally is news-driven rather than supported by volume.

Yolanda Biotech opened higher and climbed in the morning session, up 5.1% to HKD 12.41 as of 9:38 BJ, with an intraday low of HKD 12.01 and high of HKD 12.41, a range of about 3.3%. The rally was fueled by the company's recent announcement of a share buyback plan of up to RMB 100 million and a stock incentive scheme, combined with the completion of enrollment for the global Phase III trial of its core product Tinengotinib in cholangiocarcinoma. The stock has rebounded approximately 37.7% from its 52-week low of HKD 9.01. However, fundamentals remain weak, with a Q4 2025 net loss of HKD 96.2 million, widening 58.4% YoY, EPS of -HKD 0.2424, and ROE of -83.1%. The current price is still 98.2% below the 52-week high of HKD 679.5 and below the 60-day MA of HKD 23.364, with a YTD drop of 89.0%. Nevertheless, the PB ratio stands at 10.96x, highlighting lingering valuation concerns.